ARTICLE | Clinical News
SF1126 regulatory update
November 15, 2010 8:00 AM UTC
FDA granted Orphan Drug designation for Semafore's SF1126 to treat B cell chronic lymphocytic leukemia (CLL). SF1126 is in Phase I testing for the indication. The compound is a vascular targeted small...